Swedbank AB Raises Stake in Zoetis Inc. $ZTS

Swedbank AB grew its position in Zoetis Inc. (NYSE:ZTS) by 12.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,734,590 shares of the company’s stock after buying an additional 297,702 shares during the period. Swedbank AB owned approximately 0.62% of Zoetis worth $344,066,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Global Wealth Strategies & Associates purchased a new position in Zoetis in the fourth quarter worth about $25,000. Lodestone Wealth Management LLC purchased a new position in Zoetis in the fourth quarter worth about $30,000. KERR FINANCIAL PLANNING Corp purchased a new position in Zoetis in the third quarter worth about $31,000. Holos Integrated Wealth LLC purchased a new position in Zoetis in the fourth quarter worth about $32,000. Finally, Board of the Pension Protection Fund purchased a new position in Zoetis in the fourth quarter worth about $38,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Down 0.1%

ZTS opened at $112.60 on Wednesday. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The firm has a 50 day moving average price of $119.61 and a 200-day moving average price of $124.33. Zoetis Inc. has a twelve month low of $111.27 and a twelve month high of $172.23. The stock has a market capitalization of $47.36 billion, a price-to-earnings ratio of 18.70, a PEG ratio of 1.73 and a beta of 0.87.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts forecast that Zoetis Inc. will post 7.01 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.9%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is 35.22%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Bank of America lifted their target price on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, February 13th. Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. UBS Group decreased their target price on shares of Zoetis from $136.00 to $130.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Finally, Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $151.75.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.